Charles Schwab Investment Management Inc. Purchases 18,899 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Charles Schwab Investment Management Inc. boosted its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 1.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 993,813 shares of the biopharmaceutical company’s stock after acquiring an additional 18,899 shares during the period. Charles Schwab Investment Management Inc. owned 1.03% of Intra-Cellular Therapies worth $71,177,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of Intra-Cellular Therapies by 0.5% in the third quarter. Vanguard Group Inc. now owns 8,539,725 shares of the biopharmaceutical company’s stock valued at $444,834,000 after purchasing an additional 43,689 shares during the period. JPMorgan Chase & Co. raised its holdings in Intra-Cellular Therapies by 4.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,063,802 shares of the biopharmaceutical company’s stock valued at $107,503,000 after acquiring an additional 86,388 shares during the period. Wellington Management Group LLP lifted its position in shares of Intra-Cellular Therapies by 6.7% during the third quarter. Wellington Management Group LLP now owns 1,815,954 shares of the biopharmaceutical company’s stock worth $94,593,000 after acquiring an additional 114,370 shares in the last quarter. Polar Capital Holdings Plc boosted its holdings in shares of Intra-Cellular Therapies by 150.0% in the third quarter. Polar Capital Holdings Plc now owns 1,000,000 shares of the biopharmaceutical company’s stock worth $52,090,000 after acquiring an additional 600,000 shares during the period. Finally, Northern Trust Corp boosted its holdings in shares of Intra-Cellular Therapies by 1.2% in the third quarter. Northern Trust Corp now owns 948,798 shares of the biopharmaceutical company’s stock worth $49,423,000 after acquiring an additional 11,310 shares during the period. 92.33% of the stock is owned by hedge funds and other institutional investors.

Intra-Cellular Therapies Trading Down 0.9 %

Shares of NASDAQ:ITCI opened at $65.71 on Wednesday. The firm has a fifty day moving average of $68.79 and a 200 day moving average of $66.46. Intra-Cellular Therapies, Inc. has a 52-week low of $45.50 and a 52-week high of $84.89.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.15. The firm had revenue of $144.90 million during the quarter, compared to analysts’ expectations of $141.41 million. Intra-Cellular Therapies had a negative return on equity of 18.49% and a negative net margin of 21.57%. The company’s revenue for the quarter was up 52.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.46) EPS. As a group, equities analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.53 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Intra-Cellular Therapies news, EVP Michael Halstead sold 7,907 shares of Intra-Cellular Therapies stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $69.53, for a total transaction of $549,773.71. Following the transaction, the executive vice president now directly owns 29,700 shares of the company’s stock, valued at $2,065,041. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, EVP Michael Halstead sold 7,907 shares of the stock in a transaction on Monday, February 26th. The shares were sold at an average price of $69.53, for a total transaction of $549,773.71. Following the transaction, the executive vice president now owns 29,700 shares of the company’s stock, valued at approximately $2,065,041. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Sharon Mates sold 22,590 shares of the business’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $69.79, for a total transaction of $1,576,556.10. Following the completion of the sale, the chief executive officer now directly owns 1,050,309 shares of the company’s stock, valued at $73,301,065.11. The disclosure for this sale can be found here. Insiders sold a total of 168,487 shares of company stock valued at $11,364,950 over the last quarter. 3.40% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

ITCI has been the topic of a number of recent research reports. The Goldman Sachs Group increased their price objective on Intra-Cellular Therapies from $67.00 to $77.00 and gave the stock a “neutral” rating in a report on Wednesday, April 17th. Robert W. Baird raised their price objective on shares of Intra-Cellular Therapies from $83.00 to $103.00 and gave the company an “outperform” rating in a research report on Wednesday, April 17th. TD Cowen boosted their price objective on shares of Intra-Cellular Therapies from $80.00 to $90.00 and gave the company a “buy” rating in a research note on Wednesday, April 17th. Mizuho increased their target price on shares of Intra-Cellular Therapies from $82.00 to $96.00 and gave the stock a “buy” rating in a research note on Monday, April 22nd. Finally, Royal Bank of Canada restated an “outperform” rating and set a $86.00 price target on shares of Intra-Cellular Therapies in a research report on Wednesday, April 3rd. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, Intra-Cellular Therapies currently has a consensus rating of “Moderate Buy” and an average price target of $90.17.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.